Lv3
368 积分 2024-10-29 加入
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study
11天前
已完结
Alternative splicing of Scn9a exon 5: mechanistic insights and therapeutic potential in pain disorders
1个月前
已关闭
Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk
1个月前
已完结
Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial
1个月前
已完结
Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials
1个月前
已完结
Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study
2个月前
已完结
Asundexian versus Apixaban in Patients with Atrial Fibrillation
4个月前
已完结
Pharmacokinetics, pharmacodynamics and safety profile of SKB336, a selective inhibitor of coagulation factor XI/XIa in healthy subjects
4个月前
已完结
Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials
4个月前
已完结
A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis
4个月前
已完结
皖公网安备34019202002308
